MannKind Corporation (NasdaqGM : MNKD) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million on May 17, 2022. The Asset Purchase Agreement included an upfront payment of $10 million to Zealand and sales based milestones, as well as sale of certain inventory related to V-Go® and transfer of selected employees.

MannKind Corporation (NasdaqGM : MNKD) completed the acquisition of V-Go® Insulin Delivery Device from Zealand Pharma A/S (CPSE:ZEAL) for $10 million on May 29, 2022.